Cumulative effects of therapies on disability in relapsing multiple sclerosis

被引:11
|
作者
Rollot, Fabien [1 ,2 ,3 ,4 ,5 ]
Casey, Romain [1 ,2 ,3 ,4 ,5 ]
Leray, Emmanuelle [6 ,7 ]
Debouverie, Marc [8 ,9 ]
Edan, Gilles [7 ,10 ]
Wiertlewski, Sandrine [11 ,12 ]
Vukusic, Sandra [1 ,2 ,3 ,4 ,5 ]
Laplaud, David-Axel [11 ,12 ,13 ]
机构
[1] Univ Claude Bernard Lyon 1, Univ Lyon, Lyon, France
[2] Hosp Civils Lyon, Serv Neurol Sclerose Plaques Pathol Myeline & Neu, Bron, France
[3] Ctr Rech Neurosci Lyon, INSERM 1028, Observ Francais Sclerose Plaques, Lyon, France
[4] CNRS, UMR 5292, Lyon, France
[5] EUGENE DEVIC EDMUS Fdn, Bron, France
[6] Univ Rennes EHESP, REPERES EA 7449, Rennes, France
[7] CHU Rennes, CIC P 1414, Rennes, France
[8] CHU Nancy, Dept Neurol, Nancy, France
[9] Univ Lorraine, EA APEMAC 4360, Nancy, France
[10] CHU Rennes, Dept Neurol, Rennes, France
[11] CHU Nantes, Dept Neurol, Nantes, France
[12] CHU Nantes, CIC Inserm 1415, Nantes, France
[13] Ctr Rech Transplantat & Immunol, Inserm, U1064, Nantes, France
关键词
Multiple sclerosis; treatment response; cumulative effect; long-term observational study; PLACEBO-CONTROLLED TRIAL; DISEASE-MODIFYING DRUG; INTERFERON BETA-1A; NATURAL-HISTORY; DOUBLE-BLIND; PROGRESSION; EXPOSURE; BENZODIAZEPINES; ASSOCIATION; FINGOLIMOD;
D O I
10.1177/1352458520980366
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Long-term effectiveness of treatment remains a key question in multiple sclerosis (MS) and the cumulative effects of past treatment have not been investigated so far. Objective: Explore the relationship between treatment exposure and disability risk in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A total of 2285 adult patients from the French nationwide cohort were included. Outcomes were irreversible EDSS4, and conversion to secondary progression of multiple sclerosis (SPMS). Associations between treatments and risk of disability were assessed using a novel weighted cumulative exposure model, assuming a 3-year lag to account for reverse causality. This flexible approach accounts for past exposure in a multivariate Cox proportional hazards model by computing a weight function. Results: At baseline, mean +/- standard deviation age of patients was 33.4 +/- 8.9 years and 75.0% were women. A 15-year continuous treatment starting 20 years ago was associated with a decrease in risk of 26% for irreversible EDSS4, and 34% for SPMS compared to a 5-year treatment starting 10 years ago. The risk of disability decreased with increasing duration of exposure to disease-modifying treatment (DMT). Conclusion: Long-term use of treatments in RRMS has a stronger beneficial cumulative impact than only early uses and delays the occurrence of moderate disability and conversion to SPMS.
引用
收藏
页码:1760 / 1770
页数:11
相关论文
共 50 条
  • [41] Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis
    Munschauer, F.
    Giovannoni, G.
    O'Connor, P. W.
    Phillips, J. T.
    Polman, C. H.
    Pace, A.
    Kim, R.
    Hyde, R.
    Panzara, M. A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S109 - S109
  • [42] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [43] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
  • [44] Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies
    Meca-Lallana, Jose
    Garcia-Merino, Juan Antonio
    Martinez-Yelamos, Sergio
    Vidal-Jordana, Angela
    Costa, Lucienne
    Eichau, Sara
    Rovira, Alex
    Brieva, Luis
    Aguera, Eduardo
    Zarranz, Alfredo Rodriguez-Antiguedad
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (03) : 251 - 261
  • [45] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [46] Effectiveness of disease-modifying therapies in relapsing multiple sclerosis in south china
    Tao, V.
    Zhao, L.
    Au, C.
    Ng, A.
    Mok, V.
    Lau, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 531 - 532
  • [47] COST-UTILITY OF DISEASE MODIFYING THERAPIES FOR RELAPSING -REMITTING MULTIPLE SCLEROSIS
    Zimmermann, M.
    Brouwer, E.
    Tice, J. A.
    Seidner, M.
    Loos, A.
    Liu, S.
    Chapman, R. H.
    Kumar, V
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [48] Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
    Rudick, RA
    Goodkin, DE
    Jacobs, LD
    Cookfair, DL
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Granger, CV
    Simon, JH
    Alam, JJ
    Simonian, NA
    Campion, MK
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeistockGuttman, B
    Whitham, RH
    NEUROLOGY, 1997, 49 (02) : 358 - 363
  • [49] No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability
    Juenemann, Martin
    Yeniguen, Mesut
    Stolz, Erwin
    Berghoff, Martin
    JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2409 - 2410
  • [50] Two new oral disease modifying therapies in relapsing remitting multiple sclerosis
    Lebrun, C.
    de Seze, J.
    REVUE NEUROLOGIQUE, 2014, 170 (12) : 721 - 722